Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Spyros Chalkias, Howard Schwartz, Biliana Nestorova, Jing Feng, Ying Chang, Honghong Zhou, Frank J. Dutko, Darin K. Edwards, David Montefiori, Rolando Pajon, Brett Leav, Jacqueline M. Miller, Rituparna Das
doi: https://doi.org/10.1101/2022.03.04.22271830

Article Information

doi 
https://doi.org/10.1101/2022.03.04.22271830
History 
  • March 7, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Spyros Chalkias, M.D.1,*,
  2. Howard Schwartz, M.D.2,
  3. Biliana Nestorova, M.B.A.1,
  4. Jing Feng, M.S.1,
  5. Ying Chang, M.S.1,
  6. Honghong Zhou, Ph.D.1,
  7. Frank J. Dutko, Ph.D.1,
  8. Darin K. Edwards, Ph.D.1,
  9. David Montefiori, Ph.D.3,
  10. Rolando Pajon, Ph.D.1,
  11. Brett Leav, M.D.1,
  12. Jacqueline M. Miller, M.D.1 and
  13. Rituparna Das, M.D.1
  1. 1Moderna, Inc., Cambridge, Massachusetts, USA
  2. 2CMO Research Centers of America, Hollywood, Florida, USA
  3. 3Department of Surgery and Duke Human Vaccine Institute, Durham, North Carolina, USA
  1. ↵*Corresponding Author: Spyros Chalkias M.D., Spyros.Chalkias{at}modernatx.com, (617) 335 0744, Moderna, Inc., 200 Technology Square, Cambridge, Massachusetts 02139
Back to top
Posted March 07, 2022.
Download PDF
Data/Code
Email
Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
Spyros Chalkias, Howard Schwartz, Biliana Nestorova, Jing Feng, Ying Chang, Honghong Zhou, Frank J. Dutko, Darin K. Edwards, David Montefiori, Rolando Pajon, Brett Leav, Jacqueline M. Miller, Rituparna Das
medRxiv 2022.03.04.22271830; doi: https://doi.org/10.1101/2022.03.04.22271830
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area